1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1974
Treatment of malignant melanoma with methyl CCNU
Young R, Canellos G, Chabner B, Schein P, Brereton H, DeVita V. Treatment of malignant melanoma with methyl CCNU. Clinical Pharmacology & Therapeutics 1974, 15: 617-622. PMID: 4601745, DOI: 10.1002/cpt1974156617.Peer-Reviewed Original Research
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research
1966
Preliminary clinical studies with ibenzmethyzin
DeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.Peer-Reviewed Original ResearchConceptsBone marrow depressionDaily oral dosesBone marrow toxicityPreliminary clinical studyMarrow depressionHodgkin's diseaseOral dosesWeekly injectionsMarrow toxicityAdverse reactionsMalignant melanomaOral administrationClinical studiesNeoplastic diseasePatientsAntitumor activityDiseaseNauseaVomitingSomnolenceNeurologicMelanomaAtaxiaAdministrationDose